Journal
Therapeutic Advances in Medical Oncology
Publication Date
1-1-2026
Volume
18
Document Type
Open Access Publication
DOI
10.1177/17588359261467380
Rights and Permissions
Cottu P, Pascual T, Lemonnier J, et al. Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261467380. © The Author(s), 2026. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Recommended Citation
Cottu, Paul; Ma, Cynthia X; and et al., "Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer." Therapeutic Advances in Medical Oncology. 18, (2026).
https://digitalcommons.wustl.edu/oa_4/7271
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
